PALB2 and pancreatic adenocarcinoma: In a report of resected pancreatic adenocarcinoma, patients with germline BRCA1/BRCA2 and PALB2 mutations had better overall survival (OS) than patients without such mutations (median OS 46.6 months versus 23.2 months) [46].